229 related articles for article (PubMed ID: 10652352)
1. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
Segouffin-Cariou C; Billaud M
J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352
[TBL] [Abstract][Full Text] [Related]
2. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
4. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
5. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
6. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
8. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
9. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
10. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
12. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
13. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Santoro M; Carlomagno F; Romano A; Bottaro DP; Dathan NA; Grieco M; Fusco A; Vecchio G; Matoskova B; Kraus MH
Science; 1995 Jan; 267(5196):381-3. PubMed ID: 7824936
[TBL] [Abstract][Full Text] [Related]
14. The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.
Pelicci G; Troglio F; Bodini A; Melillo RM; Pettirossi V; Coda L; De Giuseppe A; Santoro M; Pelicci PG
Mol Cell Biol; 2002 Oct; 22(20):7351-63. PubMed ID: 12242309
[TBL] [Abstract][Full Text] [Related]
15. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
16. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
17. Cell signalling and gene expression mediated by RET tyrosine kinase.
Kurokawa K; Kawai K; Hashimoto M; Ito Y; Takahashi M
J Intern Med; 2003 Jun; 253(6):627-33. PubMed ID: 12755958
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of RET activation in human cancer.
Santoro M; Melillo RM; Carlomagno F; Fusco A; Vecchio G
Ann N Y Acad Sci; 2002 Jun; 963():116-21. PubMed ID: 12095936
[TBL] [Abstract][Full Text] [Related]
19. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
Besset V; Scott RP; Ibáñez CF
J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
[TBL] [Abstract][Full Text] [Related]
20. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
